Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.
Industry, Sector and Symbol
Industry Metal mining
Sub-IndustryN/A
SectorMedical
Phone310-598-5410
Debt
Current Ratio7.87
Quick Ratio7.87
Price-To-Earnings
Sales & Book Value
Annual Sales$18.45 million
Price / Sales3.03
Price / Cash Flow4.32
Price / Book730.00
Profitability
Net Income$6.58 million
Net Margins-187.13%
Return on Assets-107.02%
Miscellaneous
Employees11
OptionableNot Optionable
Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions
What is Opiant Pharmaceuticals' stock symbol?
Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."
How were Opiant Pharmaceuticals' earnings last quarter?
Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced its quarterly earnings data on Wednesday, November, 7th. The technology company reported ($0.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.21. The technology company earned $4.37 million during the quarter, compared to the consensus estimate of $4.70 million. Opiant Pharmaceuticals had a negative return on equity of 175.03% and a negative net margin of 187.13%. View Opiant Pharmaceuticals' Earnings History.
What price target have analysts set for OPNT?
1 Wall Street analysts have issued 12 month target prices for Opiant Pharmaceuticals' shares. Their predictions range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 187.7% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.
What is the consensus analysts' recommendation for Opiant Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.
Has Opiant Pharmaceuticals been receiving favorable news coverage?
Media coverage about OPNT stock has trended positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Opiant Pharmaceuticals earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned media coverage about the technology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of Opiant Pharmaceuticals' key competitors?
Some companies that are related to Opiant Pharmaceuticals include Fission Uranium (FCUUF), Amerigo Resources (ARREF), Rubicon Minerals (RBYCF), Jaguar Mining (JAGGF), Wealth Minerals (WMLLF), Atlatsa Resources (ATLRF), Santa Fe Gold (SFEG), Silver Bull Resources (SVBL), Alderon Iron Ore (AXXDF), US Gold (USAU), Pacific Booker Minerals (PBMLF), Quantum Materials (QTMM), Avalon Advanced Materials (AVLNF), Westwater Resources (WWR) and Quaterra Resources (QTRRF).
Who are Opiant Pharmaceuticals' key executives?
Opiant Pharmaceuticals' management team includes the folowing people:
- Dr. Roger Crystal, CEO & Director (Age 42)
- Mr. David D. O'Toole, Chief Financial Officer (Age 59)
- Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 48)
- Dr. Phil Skolnick, Chief Scientific Officer (Age 71)
- Mr. Quan Vu, VP of Corp. Devel.
How do I buy shares of Opiant Pharmaceuticals?
Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Opiant Pharmaceuticals' stock price today?
One share of OPNT stock can currently be purchased for approximately $14.60.
How big of a company is Opiant Pharmaceuticals?
Opiant Pharmaceuticals has a market capitalization of $52.72 million and generates $18.45 million in revenue each year. The technology company earns $6.58 million in net income (profit) each year or $2.94 on an earnings per share basis. Opiant Pharmaceuticals employs 11 workers across the globe.
What is Opiant Pharmaceuticals' official website?
How can I contact Opiant Pharmaceuticals?
Opiant Pharmaceuticals' mailing address is 201 SANTA MONICA BOULEVARD SUITE 500, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]
MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
